R5678-ONC-1879: A Phase 1/2 Study of REGN5678 (anti-PSMAxCD28) with or without Cemiplimab (anti-PD-1) in Patients with Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated with PSMA Expression
- Title
- A Phase 1/2 Study of REGN5678 (anti-PSMAxCD28) with or without Cemiplimab (anti-PD-1) in Patients with Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated with PSMA Expression
- Principal Investigator
- Kolodney, Joanna
- Phase
- I/II (Cancer Control)
- Age Group
- Adult
- Applicable Disease Sites
- Genitourinary Cancers
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Nina Moore, RN
- Research Specialist
- Phone: +1 304-293-2991
- Email: nina.moore@hsc.wvu.edu